Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Xifaxan Clear all

Conditions: Diabetes, Obesity
Interventions: Neomycin, Rifaximin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Xifaxan; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer's Disease
Interventions: Rifaximin 550 milligrams (MG); Drug
Lead sponsor: Duke University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatic Encephalopathy, Cirrhosis
Interventions: Rifaximin, Lactulose; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 43
States / cities: Phoenix, Arizona • Coronado, California • Fresno, California + 35 more

Conditions: Cirrhosis, Liver
Interventions: App to monitor stool consistency and symptoms; Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Gulf War Syndrome
Interventions: Lactulose Breath Test, Rifaximin, Placebo; Procedure · Drug
Lead sponsor: Henry C. Lin, MD; Federal
Eligibility: 21 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Human Gastrointestinal Physiology Data
Interventions: Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: BACTERIAL VAGINOSIS
Interventions: RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Microscopic Colitis
Interventions: Rifaximin 550mg; Drug
Lead sponsor: Eugene F Yen, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
Interventions: Rifaximin SSD 40 mg IR tablet, Placebo; Drug
Lead sponsor: Jasmohan Bajaj; Federal
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pouchitis
Interventions: Rifaximin 550 MG Oral Tablet [XIFAXAN]; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Celiac Disease
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Infant/ Neonate Lumbar Puncture
Interventions: Ultrasound assisted lumbar puncture; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Crohn's Disease
Interventions: Placebo Comparator, Rifaximin; Drug
Lead sponsor: Scott Lee; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions: MNK6106, Rifaximin; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more

Conditions: IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions: rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo; Drug
Lead sponsor: Mark Pimentel, MD; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin, Lactulose; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: IgA Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance
Interventions: Rifaximin, Biospecimen Collection; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions: Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo; Drug
Lead sponsor: Tampa General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin 550 MG, Low FODMAP Diet; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions: Rifaximin (drug); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Weight Loss
Interventions: Rifaximin; Drug
Lead sponsor: Bayhealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dover, Delaware

Conditions: Microbial Colonization
Interventions: Rifaximin; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Role of Methane in Glycemic Control

A Pilot Study of Xifaxan to Treat Patients With PSC

Trial of Rifaximin in Probable Alzheimer's Disease

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Longitudinal Monitoring of Stool Characteristics

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Rifaximin SSD in Dementia Trial

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Bedside Ultrasound Assisted Pediatric Lumbar Puncture

Induction of Clinical Response Using Rifaximin in Crohn's Disease

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

Efficacy of Rifaximin With NAC in IBS-D

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance

Quality of Life and Nutritional Improvements in Cirrhotic Patients

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation